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The hemodynamic and neurohumoral effects of cum-
mulative intravenous dosesofpiroximone (MDL 19205),
a noncatecholamine, nonglycoside, imidazolederivative
with positiveinotropic and vasodilatingproperties, were
studied in eight patients with severe congestive heart
failure. A dose of 1.25 mg/kg in seven patients and 1.75
mg/kg in one patient increased cardiac index by 75%
from 1.96 to 3.41 liters/min per m2 and decreased sys-
temic vascular resistance (- 41%), right atrial (- 66%)
and pulmonary wedgepressure (- 35%) (all p < 0.005).
Mean arterial pressure was slightly reduced from 78 to
71 mm Hg (p < 0.05) and forearm blood flow increased
by 42%. Plasma norepinephrine decreased from 830 to
542 pg/ml (p < 0.05) and plasma renin activity tended
to increase. In four patients, dobutamine (15 /Lg/kg per
Severe chronic congestive heart failure is characterized by
a pronounced impairment in cardiac pump function. The
resulting decrease in cardiac output is associated with tachy-
cardia, left ventricular enlargement, increased left ventric-
ular filling pressure and increased systemic vascular resis-
tance (1). The ideal management of congestive heart failure,
therefore, should cause an improvement in cardiac work
while reducing aortic impedance and left ventricular filling
pressure (2-4).
For more than a century, cardiac glycosides have been
the mainstay of long-term therapy for congestive heart fail-
ure despite their narrow therapeutic index and modest ino-
tropic activity (5). Sympathomimetics, although effective
for the acute treatment of congestive heart failure, are not
effective orally (6). Piroximone (MDL 19205) is a new
orally active agent that has been shown in preclinical studies
(7) to combine inotropic and vasodilator properties. This
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min) produced a comparable increase in cardiac index
(+ 100%), but less decrease in pulmonary wedge pres-
sure ( - 21 versus - 41%, p < 0.05 versus piroximone)
and, unlike piroximone, significantly increased heart rate
(+ 22%, p < 0.05 versus piroximone) and heart rate-
blood pressure product (+30%, P < 0.01 versus pirox-
imone). In four other patients, a single intravenous dose
of piroximone (1 mg/kg) resulted in a 35% increase in
the first derivative of left ventricular pressure (dP/dt)
from 796to 1,068mm Hg/s (p < 0.01). Thus, piroximone
is a potent inotropic agent with an acute hemodynamic
profile that may be more favorable than that of dobu-
tamine. Because the drug is orally absorbed, clinical
trials of chronic efficacy are indicated.
imidazole derivative apparently increases contractility by
mechanisms independent of glycoside or beta-adrenergic
receptors perhaps related, in part, to phosphodiesterase-
inhibiting activity (8). It also possesses a direct action on
vascular smooth muscle, resulting in a vasodilation inde-
pendent of beta-adrenergic, muscarinic or histaminergic re-
ceptors (9).
This study was designed to determine whether piroxi-
mone has an inotropic effect in human beings, determine
the optimal intravenous dose of piroximone in patients with
refractory congestive heart failure and compare the hemo-
dynamic effects of piroximone and dobutamine.
Methods
Study patients. Two groups of male patients with severe
congestive heart failure were studied. Group I consisted of
eight patients studied in the hemodynamic laboratory. Their
mean age was 45 years (range 27 to 63). Five patients had
congestive heart failure due to ischemic heart disease and
three patients had cardiomyopathies of unknown origin. Four
patients were in class III and four in class IV by the New
York Heart Association functional classification. The du-
ration of symptomatic disease ranged from 6 months to 6
years. All patients were in stable condition and had sinus
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rhythm at the time of the study. The mean ejection fraction
obtained under current therapy by gated blood pool scan
was 16% (range 9 to 21, n = 5) and 18% (range 8 to 32,
n = 6) by M-mode echocardiography on the day of the
study, Cardiothoracic ratio was increased, averaging 0,64
(range 0.55 to 0.75).
Group II consisted of four patients who, while undergo-
ing a routine diagnostic left heart catheterization, were ex-
pressly given piroximone to determine its effect on the first
derivative of left ventricular pressure (dP/dt). The mean age
in this group was 32 years (range 20 to 42). One patient
suffered from ischemic heart disease and the three other
patients had primary cardiomyopathy. All were in functional
class Ill. Mean ejection fraction was 17% (range 13 to 20),
No patient had had a recent myocardial infarction, arterial
hypertension, significant valvular heart disease or pulmo-
nary disease at the time of the study. All remained severely
symptomatic despite therapy including a sodium-restricted
diet, digitalis, vasodilators and diuretic drugs. All vasodi-
lators were discontinued at least 48 hours before the trial.
Treatment with antiarrhythmic agents, digitalis and diuretic
drugs was maintained constant, but diuretic drugs were with-
held 011 the day of study. Digitalis was given at least 3 hours
before the first dose of piroximone although experimental
data do not show any interaction between the two drugs.
The investigative protocol and consent form were approved
by the institutional review board of the University of Min-
nesota, and written informed consent was obtained from all
patients,
Hemodynamic study. Group I. Right heart catheter-
izatior was performed using a flow-directed balloon-tipped
thermodilution catheter (Edwards Laboratories). Pulmonary
arterial. pulmonary wedge and right atrial pressure were
measured using a Gould-Statham transducer and recorded
on a Hewlett-Packard eight channel recorder. Systemic ar-
terial pressure was obtained directly from a small catheter
(Artenocath) introduced into the brachial artery. Mean pres-
sures were determined electronically. Cardiac output was
calculated by the thermodilution technique using an Ed-
wards computer. All curves were obtained in triplicate with
less than 10% variation. Heart rate was monitored contin-
uously from a single electrocardiographic lead. A 12 lead
electrocardiogram was obtained before and after the study.
Derived hemodynamic variables were calculated as follows:
cardiac index = cardiac output -i- body surface area (liters/
min per m"); stroke volume index = cardiac index -i- heart
rate (ml/beat per rrr'); systemic vascular resistance = 80 X
mean arterial pressure - right atrial pressure (dynes-s-cmr ');
pulmonary vascular resistance = 80 x pulmonary artery
pulmonary wedge pressure cardiac output
(dynes's'cm- 5) ; and left ventricular work index = mean
arterial pressure - pulmonary wedge pressure x cardiac
index (0.0136) (g/rrr'), External work of the heart was ap-
proximated by the rate-pressure product of systolic blood
pressure x heart rate (10, 11).
In six patients, M-mode echocardiograms were obtained
before the administration of the drug and the observance of
the peak hemodynamic effects. Systolic and diastolic left
ventricular dimensions were measured and the correspond-
ing volumes estimated using a corrected prolate ellipse model
(12), Stroke volume and ejection fraction were subsequently
calculated using standard formulas. Forearm blood flow and
venous capacitance were determined by plethysmography
(13) in three patients during the control state and immedi-
ately after the last injection of the drug. Forearm vascular
resistance was calculated by mean arterial pressure divided
by forearm blood flow.
Group II, Four patients received a single dose of pirox-
imone, 1 mg/kg intravenously, during a diagnostic left heart
catheterization. Hemodynamic measurements, including left
ventricular pressure recorded from a microtip catheter pres-
sure transducer (Millar Instruments) and maximal left ven-
tricular dP/dt, were obtained before and 10 minutes after
the injection.
Neurohumoral reflexes and drug levels. In group I,
plasma levels of norepinephrine by radioenzymatic assay
(Upjohn Diagnostic) (14) and renin activity by radio-
immunoassay (Roche Laboratories) (15) were determined
during the control state (2 hours of rest in the supine po-
sition) and at peak effect of the drug. Plasma drug levels
determined by high pressure liquid chromatography were
measured after the first and last dose of piroximone.
Piroximone administration. Patients were evaluated in
the postabsorptive state. Two sets of baseline control mea-
surements were made at 30 minute intervals. A test bolus
of 0.25 mg/kg of the saline solution of piroximone (2 mg/
ml) was then given intravenously and followed by succes-
sive intravenous doses of 0,5 mg/kg administered every 15
minutes. Administration of piroximone was stopped when
two successive sets of hemodynamic data (cardiac output
and pulmonary wedge pressure) varied by an average of
less than 10%. Total dose was 1.25 mg/kg in seven patients
and 1.75 mg/kg in one patient.
Hemodynamic measurements were made 10 minutes after
each dose. After the final dose of piroximone, these mea-
surements were repeated at 30 minutes and then hourly until
return of all values to within 10% of the baseline level.
Dobutamine administration. In four patients (Cases 2,
5, 7 and 8), dobutamine was progressively administered to
a rate of 15 ILg/kg per min. The hemodynamic data were
obtained at the end of 15 minutes of stable infusion.
Statistical analysis. Time course variability of hemo-
dynamic measurements with piroximone and dobutamine
was analyzed using analysis of variance for repeated mea-
sures (16). Subsequent pairwise tests between mean values
were performed using the Bonferroni test (17). Intergroup
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comparisons for control values, maximal percent changes
as well as changes in ejection fraction, renin and plasma
norepinephrine were made by Student's t test for paired
values. Analysis by two variable linear regression was used
to compare plasma levels of the drug and hemodynamic
response.
Results
Control measurements. Duplicate control values ob-
tained at 30 minute intervals before piroximone varied by
less than 6% for cardiac index and pulmonary wedge pres-
sure. The differences in other variables were only minimal
and not statistically significant. Similarly, only minor dif-
ferences were found between control values in the group
given piroximone and dobutamine. All patients showed sig-
nificant abnormalities of their hemodynamic measurements
at rest compatible with the diagnosis of severe congestive
heart failure: mean cardiac index (± standard deviation)
1.96 ± 0.25 liters/min per m2 , pulmonary wedge pressure
24.6 ± 5.6 mm Hg, right atrial pressure 9.5 ± 3.5 mm
Hg and systemic vascular resistance 1,523 ± 389
dynes-s-cm-5.
Hemodynamic response to piroximone. In group I, the
first dose of piroximone significantly increased cardiac index
and left ventricular work index and decreased right atrial
pressure and systemic resistance. Those changes were fur-
ther enhanced by the next doses, and at peak effect (Table
1) cardiac index was increased from 1.96 ± 0.25 to 3.41
± 0.48 liters/min per m2 (p < 0.005), whereas pulmonary
wedge pressure decreased from 24.6 ± 5.6 to 15.6± 2.9
mm Hg (p < 0.005). Right atrial pressure decreased from
9.5 ± 3.5 to 3.1 ± 1.9 mm Hg (p < 0.005), systemic
vascular resistance from 1,523 ± 389 to 872 ± 177
dynes-s-cm-5 (p < 0.005) and pulmonary arteriolar resis-
tance from 265 ± 109 to 177 ± 76 dynes's'cm- 5 (p <
0.005). Heart rate did not change significantly from 92.5
± 12 to 96.1 ± 13 beats/min. The mean arterial pressure
progressively decreased from 78 ± 10 to 71 ± 6 mm Hg,
becoming significant (p < 0.05) only at the highest dose.
The ejection fraction obtained by M-mode echocardiography
increased from 18 ± 8.7 to 32.3 ± 13.5% (n :::: 6, p <
0.005), mainly because of a marked decrease in end-systolic
volume, but the rate-pressure product of heart rate and sys-
tolic blood pressure remained unchanged (96.76 ± 16.28
to 96.86 ± 14.14). In all but one patient, these effects were
obtained with a total dose of 1.25 mg/kg. In one patient,
the dose of 1.75 mg/kg was needed to reach the optimal
effect. As illustrated by sequential measurements of cardiac
index and pulmonary wedge pressure (Fig. 1), 1 hour after
Table 1. Acute Hemodynamic Response to Piroximone in Eight Patients With Congestive Heart Failure
HR RAP PA PeW MAP CI SVR PAR LVWI
Case State (beats/min) (mm Hg) (mm Hg) (mmHg) (mm Hg) (liters/min per nr') (dynes-s-cm t ") (dynes's'cm- s) (g/rrr')
C 85 8 38 20 83 1.95 1,583 380 1,674
P 86 1 26 11 72 4.07 720 152 3,374
2 C 102 12 50 37 87 1.99 1,489 258 1,357
P 111 3 32 20 72 3.37 811 141 2,384
3 C 95 16 32 26 70 2.23 1,041 116 1,335
P 96 3 26 16 70 3.86 747 112 2,833
4 C 110 9 27 19 62 2.38 968 164 1,424
P 110 4 28 19 62 3.14 810 97 1,752
5 C 70 7 40 26 70 1.72 1,568 346 1,031
P 72 1 34 16 67 2.68 1,050 286 1,856
6 C 90 Jl 38 22 75 1.72 1,684 421 1,238
P 90 7 34 15 75 3.18 968 270 2,591
7 C 98 9 33 24 90 1.73 2,210 244 1,548
P 102 3 30 14 82 3.12 1,184 240 2,888
8 C 90 5 32 23 83 1.95 1,642 189 1,590
P 102 3 25 14 68 3.89 686 116 2,855
Mean ::!: SD C 92.5 ::!: 12 9.5 ::!: 3.5 36.3 ::!: 7 24.6 ::!: 5.6 77.5 ::!: 9.8 1.96 ::!: 0.25 1,523 ::!: 389 265 ::!: 108 1,399 ::!: 208
P 96.1 ± 13.1 3.1 ± 1.9 29.4 ± 3.7 15.6 ± 2.9 71 ± 5.9 3.41 ± 0.48 872 ± 177 177 ± 76 2,629 ± 554
p Value NS 0.005 0.01 0.005 0.05 0.005 0.005 0.005 0.005
C = control state; CI = cardiac index; HR = heart rate; LVWI = left ventricular work index; MAP = mean arterial pressure; NS = not significant;
p = probability; P = piroximone (1.25 mg/kg except Case 7 1.75 mg/kg): PA = mean pulmonary artery pressure; PAR = pulmonary arteriolar
resistance; PeW = pulmonary capillary wedge pressure; SD = standard deviation; SVR = systemic vascular resistance.
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Figure). Temporalresponseof cardiacindex(CI)andpulmonary
capillary wedgepressure(PCW)to successive dosesof piroximone
(MOL 19205). The increase in cardiac index and decrease in pul-
monary capillary wedge pressure from the control state (CL) is
enhanced with each dose of piroximone and significant hemody-
namic effect was seen I hour after the last dose (PosLMDL). **p
< 0.01: ***p < 0.005. n = number of patients; X ± SE =
mean ± standard error.
of piroximone. The hemodynamic changes were comparable
although slightly less striking than those obtained with the
higher dose in group I. Cardiac index increased by 53%,
pulmonary wedge pressure decreased by 38% and systemic
vascular resistance by 28%. The acute change in cardiac
contractility was estimated by the modification of left ven-
tricular maximal dP/dt, which showed a 35% increase from
796 ± 92 to 1,068 ± 97 mm Hg/s (p < 0.01).
Piroximone plasma levels. Although similar intrave-
nous doses of piroximone produced a wide variety of plasma
levels, some relation between dose and blood levels was
noted. Indeed, after the first dose of 0.5 mg/kg, plasma
levels were generally close to 0.9 ILg/ml (range 0.447 to
2.094) and after 1.25 mg/kg (cumulative dose), plasma lev-
els approached 2 ILg/ml (range 1.3 to 2.8). In total, 18
levels were obtained after intravenous doses ranging from
0.5 to 1.75 mg/kg. Two variable linear regression showed
a significant correlation between plasma levels and absolute
or relative (%) changes of all hemodynamic variables with
the exception of heart rate and pulmonary resistance: cardiac
index, r = 0.68 (Fig. 2); pulmonary wedge pressure, r =
0.61; left ventricular work index, r = 0.67; systemic vas-
cular resistance, r = 0.66 (all p < 0.01); arterial, pulmonary
and right atrial pressures, r = 0.51 (p < 0.05).
Neurohumoral response to piroximone. Control plasma
levels of norepinephrine were elevated (mean 830 ± 357
versus 175 ± 30 pg/ml in the control state) and consistently
decreased after piroximone to 592 ± 157 pg/ml (p < 0.05).
Plasma renin activity tended to increase from 32.7 ± 51 to
53.8 ± 72 ng/ml per h, but this increase did not reach the
level of significance.
Hemodynamic response to dobutamine. In four pa-
tients, dobutamine, 15 ILg/kgper min, also produced marked
changes in cardiac index from 2.03 ± 0.13 to 4.07 ± 0.52
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the last injection the drug was still exerting a hemodynamic
effect; after 2 hours, hemodynamic values were within 10%
of baseline level.
Forearm blood flow measured in three patients showed
a 42% increase from 1.65 ± 0.3 to 2.35 ± 0.7 mlilOO g
per min and forearm resistance decreased from 52 ± 10 to
33 ± 9 units (p < 0.05). Forearm venous capacitance was
not modified.
In group II, the patients received a single dose of I mg/kg
• •
• •
• Figure 2. Correlationof percent change in cardiac
• index (% d CI) to plasma concentrations of pirox-
• • imone (MOL 19205). As plasma concentration of
• piroximone increased, so did the cardiac index (p
< 0.01).
• r=O.68
• • n=18
• •
3.0 -
2.5
E
..... 2.0Ol
o
E
l/)
0 1.5C\l
ell
...J
0 1.0
::E
•
0.5
•
• •
% t. CI
368 PETEIN ET AL.
HEMODYNAMIC EFFECT OF PIROXIMONE
lACC Vo!. 4. No.2
August 1984:364-71
liters/min per m2 (p < 0.01) and left ventricular work index
from 1,560 ± 330 to 3,021 ± 643 g/m? (p < 0.05) and
decreased pulmonary wedge pressure from 26 ± 6 to 21
± 5 mm Hg (p < 0.05). Mean arterial pressure was not
significantly modified, but heart rate increased from 90 ±
16 to 111 ± 23 beats/min (p < 0.05). Systemic vascular
resistance decreased from 1,607 ± 274 to 768 ± 211
dynes-s-cm -5 (p < 0.01), but pulmonary arteriolar resis-
tance was not modified despite the increase in cardiac output
leading to an insignificant increase of pulmonary pressure.
Comparison between hemodynamic effects of pirox-
imone and dobutamine in four patients (Fig. 3). Although
the increase in cardiac index was slightly greater after do-
butamine than after piroximone ( + 100 versus + 76%), the
difference was not statistically significant and was mostly
due to a chronotropic effect. Indeed, the changes in stroke
index induced by both drugs were comparable ( +68 versus
+61%). However, dobutamine administration led to a sig-
nificant (p < 0.05) increase in heart rate ( + 22%, P < 0.05)
not seen after piroximone ( + 7%, difference not significant).
Both drugs similarly reduced the right atrial pressure, al-
though dobutamine was significantly less effective in low-
ering the pulmonary wedge pressure ( - 21 versus - 41%,
P < 0.05). The changes in pulmonary artery pressure oc-
curred in opposite directions after dobutamine and piroxi-
mone administration (+ 10 versus -20%, p < 0.01). Sys-
temic vascular resistance decreased with both drugs, the
effects of dobutamine being more pronounced ( - 52 versus
-46%, p < 0.05). Finally, the modification of the rate-
pressure product (heart rate - systolic blood pressure)
produced by the two drugs were strikingly different (p <
0.01); after piroximone administration, the rate-pressure
product remained unchanged (- 5%, not significant), whereas
dobutamine increased it by 30%.
No side effects were recorded during the entire trial. In
particular no angina or arrhythmias were seen. Instead, at
least five patients spontaneously mentioned a subjective im-
provement, particularly decreased orthopnea.
During the study, laboratory data consisting of a com-
plete blood count, electrolyte battery, blood chemistries for
renal and hepatic function, blood glucose, uric acid and
urinalysis were monitored. Data were collected before drug
administration and 1 and 7 days later. No significant changes
were seen in any of these variables after piroximone therapy.
Discussion
Mechanisms of action of piroximone. The mechanism
of action of piroximone remains largely unknown. It prob-
ably depends on several actions resulting in at least two
cardiovascular effects: positive inotropism and peripheral
vasodilation. The in vitro positive chronotropic effect ob-
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Figure 3. Comparison of the acute hemodynamic
response to piroximone (M) and dobutamine (D) in
fourpatients withheartfailure. The increase in stroke
index(SI), decrease in meanarterial pressure (MAP)
and increase in left ventricular work index (LVWI)
were comparable. Piroximone caused a greater de-
creasein pulmonary capillary wedge pressure (PCW)
and dobutamine caused a greater increase in heart
rate (HR). The rate-pressure product (HR x SBP
[systolic blood pressurel) decreased after piroxi-
moneand increased afterdobutarnine. BPM = beats/
min;C = the control state;n = numberof patients;
NS = not significant; P = peak effect.
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served ill several preparations (7,8) was not seen in our
patients who have heart failure, at the doses of piroximone
administered, and did not seem to playa role in the drug's
hemodynamic effect. Piroximone does not appear to modify
Na+K+ ATPase, but it does have a phosphodiesterase in-
hibition activity (8). The importance of this mechanism
remains to be clarified. Studies on various muscle prepa-
rations have confirmed an increase in contractile force not
mediated either by beta-adrenergic or histaminic activity.
In dogs, piroximone increases left ventricle dP/dt to the
same extent whether propranolol is present or not (18),
Moreover, the combination of piroximone and isoproterenol
produces an additive effect on guinea pig atrial rate and a
synergistic effect on contractile force (18). Piroximone also
has a vasodilating effect on an isolated perfused dog limb
(18), Since this action is enhanced by adrenergic blockade
and unaltered by sympathectomy, or by beta-adrenergic,
muscarinic or histaminic blockade, the vasodilation is likely
a direct effect on the vascular smooth muscle (9).
Hemodynamic effect of piroximone. In these patients
with severe congestive heart failure, piroximone consist-
ently improved cardiac performance by increasing cardiac
outputmd stroke volume while reducing filling pressure
(Fig, 4). Moreover, despite a slight but significant reduction
in aortic pressure, plasma norepinephrine consistently de-
creased during piroximone administration. This paradoxical
Figure 4. Changes in pulmonary capillary wedge pressure (PCW)
and stroke volume index from control state to peak effect after
piroximone in eight patients with congestive heart failure.
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response, previously observed during vasodilator therapy
(19), could be related to an improvement in cardiac per-
formance or to the effects of altered pulsatile pressure on
carotid baroreceptors (20), Likewise, the tendency of plasma
renin activity to increase after piroximone therapy might
reflect changes in renal artery baroreceptor function or renal
blood flow. The improvement in left ventricular function
was obtained without altering the rate-pressure product of
heart rate and systolic blood pressure and was clearly dose-
dependent as shown by the significant relation between al-
most all hemodynamic variables and plasma levels of pir-
oximone. Although experimental data stongly suggest a dual
mode of action (inotropism and vasodilation), it remains
difficult to separate these two effects on the basis of hemo-
dynamic measurements alone. The increase in left ventric-
ular maximal dP/dt observed in the four patients studied
during left heart catheterization supports the presence of an
inotropic effect (21,22). Although left ventricular dP/dt may
not accurately assess cardiac contractility, this isovolumic
index is known to be highly sensitive to acute changes in
inotropic state (23) and insensitive to modification of af-
terload (24), except when the changes induce a premature
opening of the aortic valve (25). This is unlikely to be the
case in our patients because the arterial diastolic pressure
remained stable (66 versus 65 mm Hg). Similarly, peak
dP/dt can be increased by augmentation of preload (22), In
our patients, however, peak dP/dt increased despite a sig-
nificant decrease (- 38%) in wedge pressure. These data
suggest that the observed change in dP/dt probably under-
estimated the actual improvement in contractility induced
by piroximone.
The 41% decrease in systemic vascular resistance ob-
served after piroximone is compatible with a direct vaso-
dilating effect. Although purely mechanical dilation of the
vessels induced by the increase in cardiac output cannot be
excluded (26), the modest decrease in arterial pressure is
suggestive of drug-induced vasodilation.
Despite the marked increase in left ventricular work in-
dex, the rate-pressure product remained unchanged. The
product of heart rate and systolic blood pressure has been
shown to be a reliable index of myocardial oxygen con-
sumption in a variety of clinical settings (10,11). This re-
lation between rate-pressure product and myocardial oxygen
consumption may be modified slightly by interventions that
either alter ventricular volume or myocardial contractility
(27,28). The effect of piroximone on this relation is un-
known. However, it is likely that an increase in oxygen
consumption inducted by an increase in contractility would
be counterbalanced by a reduction in preload and afterload.
Comparison between piroximone and dobutamine.
Dobutamine, a potent beta-agonist, has been found useful
in improving left ventricular function in patients with
congestive heart failure (29,30). The results obtained with
piroximone and dobutamine, 15 J-Lg/kg per min, in four
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patients are summarized in Figure 3. Piroximone produced
a comparable increase in stroke volume as did dobutamine,
but with a lower pulmonary wedge pressure and a lesser
increase in heart rate (p < 0.05). The effect on systemic
resistance was slightly but significantly more pronounced
after dobutamine ( - 53 versus - 46%, P < 0.05 dobutamine
versus piroximone). However, previous studies (31) sug-
gested that the decrease in resistance during dobutamine
infusion may be largely mechanical or reflex, or a combi-
nation of both, in origin. On the contrary, experimental data
(9) support a direct effect of piroximone on vascular smooth
muscle. In our patients, after piroximone therapy, the de-
crease in resistance was sufficient with regard to the change
in cardiac' output to produce a significant decrease in both
mean and systolic blood pressure ( - 12 and - 10%, P <
0.05 versus control) and this is likely to be the resultant of
a true vasodilation. Another important difference between
piroximone and dobutamine was the effect on the rate-pres-
sure product that remained nearly unchanged after piroxi-
mone administration, but increased by 30% after dobuta-
mine. Thus, if the increase in contractility was equivalent
after both drugs, piroximone may be more beneficial from
the point of view of myocardial oxygen consumption be-
cause of its vasodilating actions and the absence of a strong
positive chronotropic effect.
Therapeutic implications. The results of the present
study indicate that piroximone given intravenously is a po-
tent inotropic agent with vasodilating properties that produce
a marked increase in cardiac output and left ventricular work
with a decrease in systemic resistance. These results, com-
parable with those obtained with dobutamine, are achieved
with a greater reduction in filling pressure. Moreover, in
contrast to dobutamine, piroximone produces only minimal
changes in heart rate and systolic pressure. This may make
it particularly attractive in the setting of ischemic heart dis-
ease. Furthermore, piroximone is available in an oral form
that has proven to be the equal of the parenteral form in
preliminary animal trials (18). However, further study is
needed to investigate the efficacy of the oral form in the
long-term treatment of congestive heart failure.
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